Patents by Inventor Benjamin Douglas Sellers

Benjamin Douglas Sellers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TDO2 Inhibitors
    Publication number: 20220306635
    Abstract: Presently provided are inhibitors of cellularly expressed TD02 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
    Type: Application
    Filed: October 12, 2020
    Publication date: September 29, 2022
    Inventors: Xingyu Lin, Po-wai Yuen, Rohan Mendonca, Brendan Parr, Richard Pastor, Zhonghua Pei, Lewis Gazzard, Firoz Jaipuri, Sanjeev Kumar, Xiaokai Li, Roheeth Pavana, Hima Potturi, Venkata Velvadapu, Jesse Waldo, Zuhui Zhang, Guosheng Wu, Benjamin Douglas Sellers
  • ANTIBACTERIAL PEPTIDES AND METHODS OF USE
    Publication number: 20220135622
    Abstract: The invention provides antibacterial compositions comprising peptides that bind to a lipopolysaccharide and methods of using the same.
    Type: Application
    Filed: February 26, 2020
    Publication date: May 5, 2022
    Applicant: Genentech, Inc.
    Inventors: Thomas CLAIRFEUILLE, Emily J. HANAN, Jian Mehr-Dean PAYANDEH, Steven Thomas RUTHERFORD, Benjamin Douglas SELLERS, Nicholas John SKELTON
  • TDO2 Inhibitors
    Patent number: 10800780
    Abstract: Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: October 13, 2020
    Assignees: Genentech, Inc., NewLink Genetics Corporation
    Inventors: Xingyu Lin, Po-wai Yuen, Rohan Mendonca, Brendan Parr, Richard Pastor, Zhonghua Pei, Lewis Gazzard, Firoz Jaipuri, Sanjeev Kumar, Xiaokai Li, Roheeth Pavana, Hima Potturi, Venkata Velvadapu, Jesse Waldo, Zuhui Zhang, Guosheng Wu, Benjamin Douglas Sellers